LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Omeros Corp

Cerrado

SectorSalud

3.8 15.5

Resumen

Variación precio

24h

Actual

Mínimo

3.28

Máximo

3.84

Métricas clave

By Trading Economics

Ingresos

-2.1M

-33M

Ventas

412K

412K

BPA

-0.541

Margen de beneficio

-8,121.359

Empleados

202

EBITDA

-1.9M

-35M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+1263.64% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-242M

180M

Apertura anterior

-11.7

Cierre anterior

3.8

Noticias sobre sentimiento de mercado

By Acuity

40%

60%

129 / 380 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Omeros Corp Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

6 jun 2025, 14:31 UTC

Ganancias

New York State Retirement Fund Posts 5.84% Annual Investment Return

6 jun 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

6 jun 2025, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

6 jun 2025, 20:33 UTC

Ganancias

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 jun 2025, 19:36 UTC

Charlas de Mercado

Oil Futures Post Solid Weekly Gains -- Market Talk

6 jun 2025, 19:28 UTC

Charlas de Mercado

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

6 jun 2025, 18:46 UTC

Charlas de Mercado

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

6 jun 2025, 18:02 UTC

Charlas de Mercado

U.S. Oil Rig Count Continues to Decline -- Market Talk

6 jun 2025, 16:35 UTC

Ganancias

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 jun 2025, 16:34 UTC

Ganancias

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 jun 2025, 16:21 UTC

Charlas de Mercado

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

6 jun 2025, 16:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

6 jun 2025, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

6 jun 2025, 16:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

6 jun 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

6 jun 2025, 16:07 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

6 jun 2025, 16:07 UTC

Charlas de Mercado

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

6 jun 2025, 15:53 UTC

Charlas de Mercado

Mexican Inflation Seen Rising in May -- Market Talk

6 jun 2025, 15:36 UTC

Charlas de Mercado

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

6 jun 2025, 15:36 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

6 jun 2025, 15:33 UTC

Charlas de Mercado

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

6 jun 2025, 15:16 UTC

Charlas de Mercado

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

6 jun 2025, 15:05 UTC

Charlas de Mercado

Silver at its Highest In Nearly 15 Years -- Market Talk

6 jun 2025, 14:35 UTC

Charlas de Mercado

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

6 jun 2025, 14:28 UTC

Charlas de Mercado

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

6 jun 2025, 14:28 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

6 jun 2025, 14:28 UTC

Charlas de Mercado

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

6 jun 2025, 14:15 UTC

Charlas de Mercado

Oil Rises on U.S.-China Talks Optimism -- Market Talk

6 jun 2025, 14:12 UTC

Ganancias

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

6 jun 2025, 14:09 UTC

Ganancias

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Comparación entre iguales

Cambio de precio

Omeros Corp Esperado

Precio Objetivo

By TipRanks

1263.64% repunte

Estimación a 12 meses

Media 45 USD  1263.64%

Máximo 45 USD

Mínimo 45 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Omeros Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

1

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

6.265 / 7.49Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Weak Bullish Evidence

Sentimiento

By Acuity

129 / 380 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Omeros Corp

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.